Focus Fund GP

Focus Fund GP is the general partner and manager behind Cancer Focus Fund, an oncology-focused investment platform established in partnership with The University of Texas MD Anderson Cancer Center. Rather than operating as a traditional drug developer, the firm finances and helps advance promising investigational cancer therapies from late preclinical development into early clinical testing, especially Phase 1 and Phase 1b/2 studies. Its model combines venture capital investment with access to MD Anderson's clinical trial expertise, scientific advisory input, and oncology infrastructure. The fund's portfolio spans immunotherapy, cell therapy, precision oncology, radiopharmaceuticals, and synthetic immune therapies through investments in portfolio companies such as Nectin Therapeutics, Eisbach Bio, ISA, KAHR, March Biosciences, ImmunoGenesis, Starget Pharma, and Mereo BioPharma. Focus Fund GP is therefore healthcare-related, but it is best classified as an oncology investment manager rather than a biotech operating company with a proprietary internal pipeline.